zurück

Casirivimab / imdevimab (COVID-19 infection, patients aged ≥ 12 years)


Subject:

  • Active Substance: Casirivimab / imdevimab
  • Name: Ronapreve®
  • Therapeutic area: COVID-19 infection
  • Pharmaceutical company: Roche Pharma AG


Time table:

  • Start: 15.04.2022
  • Final decision by G-BA: 06.10.2022


Final decision:

  1. Adults and adolescents with infection with a viral variant against which casirivimab / imdevimab does not show sufficient efficacy: No additional benefit proved
  2. Adults and adolescents without complete immunization and with infection with a viral variant against which casirivimab / imdevimab does show sufficient efficacy: Hint for a minor additional benefit
  3. Adults and adolescents with complete immunization and with infection with a viral variant against which casirivimab / imdevimab does not show sufficient efficacy: No additional benefit proved